Vaxil Bio Ltd.
VXLLF
$0.02
-$0.13-85.27%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 60.66% | 345.07% | -28.17% | -13.03% | 73.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.94% | 345.07% | -28.17% | -13.03% | 20.00% |
| Operating Income | -51.94% | -345.07% | 28.17% | 13.03% | -20.00% |
| Income Before Tax | -57.58% | -- | 45.08% | 184.69% | -13.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.58% | -- | 45.08% | 184.69% | -13.49% |
| Earnings from Discontinued Operations | -- | 114.01% | -- | 184.31% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.58% | 2,704.46% | 59.61% | 184.92% | -13.49% |
| EBIT | -51.94% | -345.07% | 28.17% | 13.03% | -20.00% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -8.43% | 2,398.25% | 59.54% | 184.73% | -13.38% |
| Normalized Basic EPS | -9.01% | -- | 45.00% | 184.29% | -13.27% |
| EPS Diluted | -8.43% | 2,398.25% | 59.54% | 184.73% | -13.38% |
| Normalized Diluted EPS | -9.01% | -- | 45.00% | 184.29% | -13.27% |
| Average Basic Shares Outstanding | 45.42% | 13.94% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 45.42% | 13.94% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |